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~~~~~ ~ 
To examine whether leukotrienes could increase blood-brain barrier permeability, rats were anesthetized and injected 
intravenously with Evans blue. Ten microliters of vehicle, of leukotrienes B4, C4, or E4, or of arachidonic acid was 
injected over 1 hour directly into the brain parenchyma. The percentage of the total surface area of Evans blue 
extravasation in a coronal section of brain centered on the injection site was then determined as an estimate of blood- 
brain barrier permeability. Leukotrienes B4, C4, and Ed, and arachidonic acid all increased blood-brain barrier perme- 
ability, but this effect was lost when the total dose was reduced to 20 ng. Increased blood-brain barrier permeability 
induced by arachidonic acid could be prevented by pretreatment with the lipoxygenase inhibitor BW755C, but not 
with indomethacin. Leukotrienes may play a role in the development of increased blood-brain barrier permeability 
after cerebral injury. 
Black KL, Hoff JT: Leukotrienes increase blood-brain barrier permeability following intraparenchymal 
injections in rats. Ann Neurol 18:349-351, 1985 
Arachidonic acid is metabolized by means of two path- 
ways: cyclooxygenase, leading to the formation of 
prostaglandins, and lipoxygenase, leading to the pro- 
duction of leukotrienes. Prostaglandins have been im- 
plicated in the pathogenesis of cerebral ischemia. This 
is in part supported by studies showing that cerebral 
blood flow in ischemic brain is increased after treat- 
ment with cyclooxygenase inhibitors and prostacyclin 
[ 3 ) .  Leukotrienes have been shown to increase vascu- 
lar permeability in postcapillaty venules, increase 
blood flow, and elicit erythema and wheal formation in 
skin {lo). Leukotriene concentrations are reportedly 
increased in cerebral ischemia [7}, and we recently 
noted that the injection of leukotriene C4 directly into 
brain parenchyma increased blood-brain barrier 
(BBB) permeability [2). Consequently, leukotrienes 
may play a role in the pathogenesis of vasogenic cere- 
bral edema E2, 3, 7). 
This study was designed to determine (1) whether 
intraparenchymal injections of leukotriene (LT) Bq, 
LTC4, or LTE4, or arachidonic acid increase BBB per- 
meability; and (2) whether the lipoxygenase inhibitor 
BW75 5C 13-amino- I-( 3-(trifluoromethylphenyl)-2-pyra- 
zoline) {S, 9) prevents the increased BBB permeabil- 
ity induced by arachidonic acid. 
Materials and Methods 
Wistar rats weighing 250 to 350 gm were anesthetized with 
pentobarbital (40 mg per kilogram of body weight) injected 
intraperitoneally. PE-10 polyethylene catheters were in- 
serted into the femoral artery and vein. The arterial catheter 
was connected to a blood pressure transducer and systemic 
arterial blood pressure was monitored continuously. Buf- 
fered Evans blue solution (0.5 ml) was then injected into the 
femoral vein. A burrhole was made over the left frontal 
cortex. A 10-pl syringe (J and W Scientific Inc) with a deac- 
tivated fused silica needle (125 pm in diameter) was 
mounted on the arm of a stereotaxic frame. With the aid of 
magnification, the tip of the needle was manipulated 3.5 mm 
deep into the brain parenchyma and then withdrawn 1 mm. 
The final depth into the parenchyma was therefore 2.5 mm, 
corresponding to the gray-white matter interface. 
Ten microliters of either saline solution, water, 6.5% 
methanol in saline, LTB4, LTC4, LTC4, LTE4, or arachidonic 
acid was injected into the parenchyma slowly over 1 hour. 
Five animals injected with arachidonic acid were given 
BW755C (40 mg/kg) intraperitoneally 1 hour prior to arachi- 
donic acid injection, and 5 animals were given indomethacin 
(6 mg/kg) intraperitoneally 1 hour prior to arachidonic acid 
injection. Rats were decapitated 1 hour after the intraparen- 
chymal injection and their brains were removed and frozen. 
The frozen brains were sliced coronally through the plane of 
injection. The surface of the slice was photographed and, 
using polar planimetry, the area of Evans blue extravasation 
was estimated as the percentage of total surface area. 
Leukotrienes were supplied by Dr R. Rokach of Merck- 
Frosst Inc, Canada. LTC4 and LTE4 were received in water at 
a concentration of 0.2 mg/ml. LTB4 was received in 65% 
methanol in water at a concentration of 0.1 mglml. Leuko- 
trienes were subsequently diluted in saline. They were di- 
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TOTAL DOSE OF LEUKOTRIENE 
F i g  I .  Percentage of area of Evans brue extravasation in a coro- 
nal section of brain centered on the injection site afer a 1 0 - d  
injection of leukotriene B4, C4, or E4 over 1 hour. 
CONTROL 
INWMETHACIN (bmp/kgI 
BW755C (40mg/kg)  
*P<OOO1 (Cmnporad lo c ~ l l r o l )  T 
I HOUR ARACHIDONIC ACID 
INJECTION 
F i g  2. Percentage of area of Evans blue extravasation after a 
10-pl injection of  arachidonic acid (I0 pg total dose) over 1 
hour. Five animals were pretreated with indomethacin and 5 
were pretreated with BW755C. 
vided into small aliquots and stored in glass vials that were 
vacuum sealed and frozen at - 70°C. The total dose of LTB4 
injected did not exceed 100 ng per brain since the methanol 
content would then have been greater than 6.5%. In prelimi- 
nary studies we found that saline solutions with a methanol 
concentration greater than 6.5% produced some disruption 
in the BBB. Indomethacin and free arachidonic acid were 
obtained from Sigma. Free arachidonic acid was dissolved in 
0.3 M sodium hydroxide and diluted in saline to a concentra- 
tion of 1.0 mg/rnl. BW755C was agift of Wellcome Research 
Laboratories, Kent, England. BW755C was dissolved in 
saline to a final concentration of 20 mg/ml. 
An analysis of variance was used for statistical analysis. 
Results 
Except for negligible blue staining along the insertion 
tract of the needle, none of the rats injected with saline 
or water had evidence of Evans blue extravasation. The 
percentage of blue area in rats injected with 6.5% 
methanol was also negligible (0.68 k 0.21% of the 
area of the left hemisphere in the plane of injection). 
Animals injected with LTB4, LTC4, or LTE4 had 
significant extravasation of Evans blue in the area of 
injection (Fig 1). 
Arachidonic acid injection also resulted in extravasa- 
tion of Evans blue. This effect was, however, pre- 
vented by bpoxygenase inhibition with ~ ~ 7 5 5 ~ ~  but 
not by indomethacin (Figs 2, 3) .  
in all groups. 
Discussion 
Moskowitz and colleagues [7) reported increased 
levels of leukotrienes after cerebral ischemia and re- 
perfusion in the gerbil brain and suggested that cortical 
Fig 3.  Coronal section through the plane of arachidonic acid 
injection after (A) pretreatment with indomethacin and (B) pre- 
treatment with BW755C. The amount of Evans blue extrauasa- 
creased afer pretreatment with BW755C. 
pressure remained within physiolo~cd limits tion seen in the [eft hmisphere (arrows in A) is &- 
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gray matter was the most likely source of leukotriene 
synthesis. Since leukotrienes are potent vasoconstric- 
tors [ll] and they increase vascular permeability r2, 
101, some investigators suspect that leukotrienes are 
involved in the pathogenesis of brain damage following 
cerebral ischemia [2, 7, 111. 
Our study demonstrates that LTB4, LTC4, or LTE4 
(>20 ng) injected directly into brain parenchyma 
significantly increases BBB permeability. This effect is 
lost when the total local dose is less than 20 ng. The 
amount of leukotriene required to produce vasogenic 
edema by injection into the brain is, therefore, several 
orders of magnitude higher than that present in the 
cortex after ischemia-reperfusion experiments. The 
discrepancy may be attributed to: (1) leukotrienes have 
a short half-life; the baseline level of leukotriene dur- 
ing the 1-hour injection may be lower than the actual 
dose injected; (2) a longer time interval of exposure 
may be required for smaller doses of leukotrienes to 
increase BBB Permeability; and (3) measurement of 
leukotrienes in lesions that primarily cause the vaso- 
genic form of edema may reveal leukotriene levels 
higher than those in ischemic edema. Studies to deter- 
mine whether a lipoxygenase inhibitor will decrease 
vasogenic edema in these conditions are warranted. 
Other investigators have shown that arachidonic acid 
produces cerebral edema. The induction of brain 
edema by arachidonic acid is dose dependent and the 
resulting edema becomes maximal between 24 and 48 
hours. The edema is reduced by pretreatment with 
dexamethasone but not by indomerhacin {51. Inter- 
estingly, dexamethasone is reported to decrease leu- 
kotriene synthesis (41. 
In the present study the lipoxygenase inhibitor 
BW7 5 5C prevented the vasogenic edema normally 
caused by arachidonic acid. BW755C has also been 
shown to inhibit cyclooxygenase 181. The protective 
effect of BW755C is unlikely to be related to its effect 
on cyclooxygenase, since indomethacin, at a dose re- 
ported to inhibit cyclooxygenase [l], did not provide a 
similar protective effect. Our findings suggest that the 
production of vasogenic edema by arachidonic acid is 
dependent on products of the 5-lipoxygenase enzyme, 
i.e., leukotrienes, rather than the products of cyclooxy- 
genase. 
Caronna and co-workers 153 suggested that the abii- 
ity of arachidonic acid to produce brain edema is not 
specific. They also reported increased edema after in- 
jections of other polyunsaturated fatty acids, but not 
saturated fatty acids. Homa and colleagues [b],  how- 
ever, recently reported that polyunsaturated fatty 
acids, but not saturated fatty acids, stimulate the forma- 
tion of lipoxygenase products from arachidonic acid. 
Theoretically, therefore, other polyunsaturated fatty 
acids might increase edema by increasing the conver- 
sion of arachidonic acid to leukotrienes. 
In our study, LTB4 produced a greater increase in 
BBB permeability than the other leukotrienes. 
Whether this relates to the ability of LTB4 to act as a 
chemotactic factor attracting leukocytes, which in turn 
may produce more leukotrienes, is speculative. 
We believe that the development of vasogenic cere- 
bral edema is multifactorial and depends on the stimuli 
inducing the edema process. This study demonstrates 
that leukotrienes do induce vasogenic edema and that 
the ability of arachidonic acid to induce edema can be 
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